The FDA is reviewing the increase in adult prescription stimulant use and ongoing shortages, particularly among adults aged 31 to 40 years.

Stimulant dispensing has surged, possibly due to the COVID-19 pandemic and relaxed regulations around telemedicine prescribing. Ongoing shortages have created barriers for patients with ADHD. The FDA is partnering with the DEA and other federal agencies to assess appropriate use, communicate the risks of nonmedical use, and mitigate disruptions. Data do not suggest a proportional rise in nonmedical stimulant use, with evidence indicating sporadic use for performance enhancement. Despite increased prescribing, shortages persist, and the FDA remains engaged in collaborative efforts to alleviate these shortages while supporting access to appropriate treatment.

Source: JAMA Psychiatry